• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

QuiO Raises $1M for Sensor-Smart Injection Devices for Drug Delivery

by Fred Pennic 10/03/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

QuiO Raises $1M for Sensor-Smart Injection Devices for Drug Delivery

QuiO (pronounced kwee-oh), a digital healthcare startup developing sensor-driven smart injection devices and connected cloud-based software for the clinical trial and chronic disease market has raised $1.05 million in seed funding.  The round was led by undisclosed investors with expertise in the health insurance, pharmaceutical and clinical research industries. 

The company plans to utilize the funding to finish development of its lead SmartinjectorTM device, which leverages a propriety design for accepting all of the most common syringes and delivering even the most sensitive and viscous biologics.  Additionally, the company is preparing for pilots and a 510(k) submission.

Medication non-adherence poses significant clinical and economic problems to healthcare systems globally, especially involving chronic disease patients who must self-inject at home. The emergence of the internet of medical things (IoMT) has shown success in addressing the issue, including inhaler sensors, connected pill bottles, and other adherence monitoring devices. 

However, patients taking injectable therapies do not have access to such tools today, and average adherence rates can be as low as 50%.  Poor adherence to injectable therapies results in over $14 billion in avoidable medical costs and $22 billion in lost pharmaceutical revenue each year in the United States alone. 

Instead of focusing on price, QuiO believes there is an opportunity to improve the value that patients (and healthcare systems) receive from these expensive therapies. Founded in early 2014 by  Alex Dahmani while pursuing a Ph.D. at Columbia University in microbiology & immunology, QuiO is developing the first real-time adherence monitoring solution for injectable therapies.  The solution is powered by a fully connected drug delivery device platform. 
 
SmartinjectorTM
 
The company’s SmartinjectorTM devices are designed to make self-injection easy and reliable for patients, preventing common mistakes and ensuring the full dose is delivered.  Each SmartinjectorTM records injection performance, and wirelessly communicates data to the company’s cloud-based software platform.
 
Connected Drug Delivery Device Platform
 
The HIPAA-compliant platform includes a secure web dashboard with analytics and communication tools that enable caregivers to remotely monitor dosing activity and deliver timely support to patients in need.  The platform also collects data from 3rd party devices, including weight scales, activity trackers and glucose meters, providing a holistic and continuous view of each patient’s health outside of the clinic. 

Competing wireless injection devices require additional hardware and extensive setup and syncing, which may limit their applicability, burden the patient and compromise the data generated.  SmartinjectorTM devices are fully connected, enabling real-time wireless data transmission without any patient input, smartphone or syncing required. 

“With over 15 million Americans prescribed an injectable therapy today, we see a large and growing need for a comprehensive drug delivery and adherence monitoring solution,” says Alex Dahmani, co-founder and CEO of QuiO in a statement.  “Injectable therapies, including biologics and biosimilars, represent the future of medicine, making up nearly half of the pharmaceutical pipeline. These are amazing therapies, and our technology is designed to help them reach their full potential.  We may even help move cancer therapies out of the clinic, enabling patients to safely treat themselves at home.”

 

To date the company has filed four patents and finished development of the final prototype and connected software. QuiO is also working with one of the largest specialty pharmacies in the US, and have begun talks with three out of the top ten global pharma companies. 
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Medication Adherence, QuiO, Smart Injection Devices

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |